6533b862fe1ef96bd12c6c65
RESEARCH PRODUCT
Triple therapy with first-generation Protease Inhibitors for patients with genotype 1 chronic hepatitis C: Recommendations of the Italian Association for the Study of the Liver (AISF)
Savino BrunoMario RizzettoMaria RendinaPaolo CaraceniAntonio CraxìMarco MarzioniAlessia CiancioLuca ValentiAlessandra MangiaMassimo PuotiAlfredo AlbertiFerruccio BoninoBarbara CocoMaria Grazia RumiMassimo ColomboGiovanni Battista GaetaDavide BitettoRaffaele BrunoPietro AndreoneSalvatore PettaAlessio AghemoMaurizia Rossana Brunettosubject
Oncologymedicine.medical_specialtyProlinePegylated-interferonAlpha interferonHepacivirusPharmacologyAntiviral AgentsTelaprevirTelaprevirPolyethylene GlycolsHCV THERAPYchemistry.chemical_compoundLiver diseaseDrug TherapyPegylated interferonBoceprevirInternal medicineRibavirinmedicineHumansProtease InhibitorsChronicBoceprevir; Cirrhosis; Hepatitis C; Pegylated-interferon; Ribavirin; Telaprevir; Antiviral Agents; Drug Carriers; Drug Therapy Combination; Hepacivirus; Hepatitis C Chronic; Humans; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Ribavirin; Gastroenterology; HepatologyBoceprevirDrug CarriersHepatologybusiness.industryRibavirinGastroenterologyInterferon-alphaHepatitis CHepatologyHepatitis C Chronicmedicine.diseaseHepatitis CCirrhosischemistryCombinationDrug Therapy CombinationbusinessOligopeptidesmedicine.drugdescription
AbstractThe first-generation Protease Inhibitors Boceprevir and Telaprevir administered in triple therapy regimens with Peg-interferon alpha and Ribavirin have been proven effective in increasing the rate of Sustained Virological Response in both naive and treatment-experienced patients with chronic genotype-1 hepatitis C. However, at the individual level, the therapeutic advantage of triple therapy is highly variable and results from the combination of multiple factors related to the characteristics of patient, viral status and liver disease.The recommendations presented are promoted by the Italian Association for the Study of the Liver, with the aim to help the physician in the decision-making process as well as to manage patients during treatment with triple therapy.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2013-06-06 |